Moxey J, et al. - Data from 5 centers in the Australian Scleroderma Cohort Study (ASCS) was systematically evaluated to examine the prevalence of anti-neutrophil cytoplasmic antibodies (ANCA) in systemic sclerosis (SSc) cohort and also to investigate the relationship between ANCA and SSc clinical aspects, other autoantibodies, treatments, and mortality as well. They observed anti-proteinase-3 (anti-PR3) more frequent as compared to anti-MPO (13.8% and 11.2% of ANCA-positive patients, respectively). After adjusting for anti-Scl-70 antibodies, they also found an association between ANCA-positive status and interstitial lung disease (ILD). They recorded pulmonary embolism (PE) more common among ANCA-positive cases and subjects with anti-PR3-positive. Hence, they recommended ANCA testing in SSc as it recognized people with worse prognosis who need close monitoring for adverse outcomes.